The likelihood that a person with early-stage non-small cell lung cancer will receive curative treatment still varies considerably by race, even though 3 decades have passed since researchers first ...
TRIANA Biomedicines Announces First Patient Dosed in a Phase 1/2 Trial Evaluating TRI-611 for the Treatment of ALK+ Non-small Cell Lung Cancer ...
bioAffinity Technologies Inc. BIAF shares are down during Thursday’s premarket session. Over the last week, the stock has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results